Aarti Drugs 미래 성장

Future 기준 확인 4/6

Aarti Drugs (는) 각각 연간 31.5% 및 13.4% 수익과 수익이 증가할 것으로 예상됩니다. EPS는 연간 31.5% 만큼 성장할 것으로 예상됩니다. 자기자본이익률은 3년 후 17.7% 로 예상됩니다.

주요 정보

31.5%

수익 성장률

31.5%

EPS 성장률

Pharmaceuticals 수익 성장	17.5%
매출 성장률	13.4%
향후 자기자본 수익률	17.7%
애널리스트 커버리지	Low
마지막 업데이트	25 Oct 2024

최근 미래 성장 업데이트

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Recent updates

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Sep 20

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Sep 05

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

May 04

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Feb 01

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Jan 30

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

May 17

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Nov 22

We Take A Look At Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Has Earned Their Pay Packet

Aug 28

Here's Why We Think Aarti Drugs (NSE:AARTIDRUGS) Is Well Worth Watching

Aug 19

Is Aarti Drugs Limited (NSE:AARTIDRUGS) Expensive For A Reason? A Look At Its Intrinsic Value

May 17

Here's Why I Think Aarti Drugs (NSE:AARTIDRUGS) Is An Interesting Stock

Apr 04

Does Aarti Drugs (NSE:AARTIDRUGS) Have A Healthy Balance Sheet?

Mar 17

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Mar 02

Aarti Drugs' (NSE:AARTIDRUGS) Wonderful 432% Share Price Increase Shows How Capitalism Can Build Wealth

Jan 07

If You Like EPS Growth Then Check Out Aarti Drugs (NSE:AARTIDRUGS) Before It's Too Late

Dec 23

Aarti Drugs (NSE:AARTIDRUGS) Seems To Use Debt Quite Sensibly

Dec 08

Aarti Drugs Limited's (NSE:AARTIDRUGS) Fundamentals Look Pretty Strong: Could The Market Be Wrong About The Stock?

Nov 23

How Much Of Aarti Drugs Limited (NSE:AARTIDRUGS) Do Insiders Own?

Nov 08

수익 및 매출 성장 예측

NSEI:AARTIDRUGS - 애널리스트의 미래 추정치 및 과거 재무 데이터 (INR Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
3/31/2027	32,612	3,107	1,443	2,943	1
3/31/2026	28,695	2,467	773	2,273	1
3/31/2025	24,560	1,561	1,315	3,315	1
9/30/2024	23,796	1,522	1,019	3,082	N/A
6/30/2024	24,228	1,568	N/A	N/A	N/A
3/31/2024	25,286	1,714	1,326	3,589	N/A
12/31/2023	26,510	1,802	N/A	N/A	N/A
9/30/2023	27,090	1,802	1,213	3,171	N/A
6/30/2023	27,552	1,794	N/A	N/A	N/A
3/31/2023	27,161	1,663	-315	1,333	N/A
12/31/2022	26,679	1,656	N/A	N/A	N/A
9/30/2022	26,387	1,872	-836	700	N/A
6/30/2022	25,306	1,910	N/A	N/A	N/A
3/31/2022	24,886	2,050	-816	704	N/A
12/31/2021	22,961	2,014	N/A	N/A	N/A
9/30/2021	21,916	2,111	137	1,322	N/A
6/30/2021	21,901	2,438	N/A	N/A	N/A
3/31/2021	21,548	2,804	667	1,550	N/A
12/31/2020	21,027	2,876	N/A	N/A	N/A
9/30/2020	20,459	2,474	1,338	2,070	N/A
6/30/2020	19,453	2,044	N/A	N/A	N/A
3/31/2020	18,061	1,414	2,028	2,507	N/A
12/31/2019	18,156	1,100	N/A	N/A	N/A
9/30/2019	17,222	1,031	N/A	N/A	N/A
6/30/2019	15,921	888	N/A	N/A	N/A
3/31/2019	15,609	898	688	1,431	N/A
12/31/2018	14,136	863	N/A	N/A	N/A
9/30/2018	13,689	887	N/A	N/A	N/A
6/30/2018	13,407	943	N/A	N/A	N/A
3/31/2018	12,436	823	N/A	698	N/A
12/31/2017	11,592	790	N/A	N/A	N/A
9/30/2017	11,340	735	N/A	N/A	N/A
6/30/2017	11,569	721	N/A	N/A	N/A
3/31/2017	11,952	818	N/A	1,748	N/A
12/31/2016	12,102	785	N/A	N/A	N/A
9/30/2016	11,856	776	N/A	N/A	N/A
6/30/2016	11,431	713	N/A	N/A	N/A
3/31/2016	11,349	687	N/A	1,333	N/A
12/31/2015	11,101	686	N/A	N/A	N/A
9/30/2015	11,047	744	N/A	N/A	N/A
6/30/2015	11,180	774	N/A	N/A	N/A
3/31/2015	10,943	773	N/A	1,046	N/A
12/31/2014	10,868	807	N/A	N/A	N/A
9/30/2014	10,490	721	N/A	N/A	N/A
6/30/2014	10,109	662	N/A	N/A	N/A
3/31/2014	9,699	608	N/A	954	N/A
12/31/2013	9,083	526	N/A	N/A	N/A

애널리스트 미래 성장 예측

수입 대 저축률: AARTIDRUGS 의 연간 예상 수익 증가율( 31.5% )이 saving rate( 6.7% 보다 높습니다. ).

수익 vs 시장: AARTIDRUGS 의 연간 수익( 31.5% ) Indian 시장( 18.1% 보다 빠르게 성장할 것으로 예상됩니다. 18.1% 연간).

고성장 수익: AARTIDRUGS 의 수입은 향후 3년 동안 상당히 증가할 것으로 예상됩니다.

수익 대 시장: AARTIDRUGS 의 수익(연간 13.4% ) Indian 시장( 10.5% 보다 빠르게 성장할 것으로 예상됩니다. 10.5% 연간).

고성장 수익: AARTIDRUGS 의 수익(연간 13.4% )은 연간 20% 보다 느리게 증가할 것으로 예상됩니다.

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: AARTIDRUGS 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 17.7 %).

성장 기업 발견

기업 분석 및 재무 데이터 현황

데이터	마지막 업데이트(UTC 시간)
기업 분석	2024/12/23 03:29
장 마감 주가	2024/12/23 00:00
수익	2024/09/30
연간 수익	2024/03/31

데이터 소스

기업 분석에 사용된 데이터는 S&P Global Market Intelligence LLC의 데이터입니다. 이 보고서를 생성하기 위해 분석 모델에 사용된 데이터는 다음과 같습니다. 데이터는 정규화되어 있으므로 소스가 제공되기까지 지연이 발생할 수 있습니다.

패키지	데이터	기간	미국 소스 예시 ^*
회사 재무	10년	손익 계산서 현금 흐름표 대차 대조표	SEC 양식 10-K SEC 양식 10-Q
애널리스트 컨센서스 추정치	+3년	재무 예측 애널리스트 목표가	애널리스트 연구 보고서 Blue Matrix
시장 가격	30년	주식 가격 배당금, 분할 및 액션	ICE 시장 데이터 SEC 양식 S-1
소유권	10년	최대 주주 내부자 거래	SEC 양식 4 SEC 양식 13D
관리	10년	리더십 팀 이사회	SEC 양식 10-K SEC 양식 DEF 14A
주요 개발 사항	10년	회사 공지 사항	SEC 양식 8-K

* 미국 증권의 경우, 미국 외 지역의 규제 양식 및 출처가 사용된 예입니다.

명시되지 않는 한 모든 재무 데이터는 1년을 기준으로 하지만 분기별로 업데이트됩니다. 이를 후행 12개월(TTM) 또는 최근 12개월(LTM) 데이터라고 합니다. 여기에서 자세히 알아보세요.

분석 모델 및 눈송이

이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 Github 페이지에서 확인할 수 있으며, 보고서 사용 방법에 대한 가이드와 튜토리얼도 유튜브에서 확인할 수 있습니다.

Simply 월스트리트 분석 모델을 설계하고 구축한 세계적인 수준의 팀에 대해 알아보세요.

산업 및 부문 메트릭

업계 및 섹션 지표는 Simply Wall St에서 6시간마다 계산되며, 자세한 내용은 확인할 수 있습니다.

애널리스트 출처

Aarti Drugs Limited 4 애널리스트 중 1 애널리스트가 보고서의 입력 자료로 사용된 매출 또는 수익 추정치를 제출했습니다. 애널리스트의 제출 자료는 하루 종일 업데이트됩니다.

분석가	교육기관
Rashmi Sancheti Shetty	CGS International
Rashmi Sancheti Shetty	Dolat Capital Market Pvt. Ltd.
Kameswari V. S. Chavali	FirstCall Research

Aarti Drugs 미래 성장

Future 기준 확인 4/6

주요 정보

최근 미래 성장 업데이트

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Price target decreased by 9.4% to ₹562

Price target increased by 22% to ₹578

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Recent updates

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Aarti Drugs Limited Announces Restoration of Manufacturing Process of Particular Product At T-150 Unit

Second quarter 2025 earnings released: EPS: ₹3.84 (vs ₹4.29 in 2Q 2024)

Aarti Drugs Limited to Report Q2, 2025 Results on Oct 24, 2024

High number of new directors

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited, Annual General Meeting, Sep 20, 2024

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

Aarti Drugs Limited to Report Q1, 2025 Results on Jul 26, 2024

Full year 2024 earnings: EPS in line with expectations, revenues disappoint

High number of new directors

Aarti Drugs Limited Announces Executive Cessation

Price target decreased by 9.4% to ₹562

Upcoming dividend of ₹1.00 per share at 0.2% yield

Third quarter 2024 earnings released: EPS: ₹3.99 (vs ₹3.96 in 3Q 2023)

Aarti Drugs Limited Announces Interim Dividend for the Financial Year 2023- 24

Aarti Drugs Limited to Report Q3, 2024 Results on Jan 24, 2024

Second quarter 2024 earnings released: EPS: ₹4.29 (vs ₹4.19 in 2Q 2023)

Now 21% undervalued

Aarti Drugs Limited to Report Q2, 2024 Results on Oct 19, 2023

We Discuss Why Aarti Drugs Limited's (NSE:AARTIDRUGS) CEO Will Find It Hard To Get A Pay Rise From Shareholders This Year

Now 21% undervalued

Aarti Drugs (NSE:AARTIDRUGS) Has A Somewhat Strained Balance Sheet

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Aarti Drugs Limited, Annual General Meeting, Sep 26, 2023

Price target increased by 22% to ₹578

Aarti Drugs Limited (BSE:524348) announces an Equity Buyback for 665,000 shares, representing 0.72% for INR 598.5 million.

First quarter 2024 earnings released: EPS: ₹5.17 (vs ₹3.76 in 1Q 2023)

Aarti Drugs Limited to Report Q1, 2024 Results on Jul 21, 2023

Is Aarti Drugs (NSE:AARTIDRUGS) A Risky Investment?

Full year 2023 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improves as stock rises 20%

Investor sentiment improves as stock rises 17%

Upcoming dividend of ₹1.00 per share at 0.2% yield

Aarti Drugs Limited Recorded A 9.0% Miss On Revenue: Analysts Are Revisiting Their Models

Price target decreased by 8.0% to ₹473

Aarti Drugs (NSE:AARTIDRUGS) Is Due To Pay A Dividend Of ₹1.00

Third quarter 2023 earnings released: EPS: ₹3.96 (vs ₹6.30 in 3Q 2022)

Aarti Drugs Limited Declares Interim Dividend for the Financial Year 2022-23

Aarti Drugs Limited to Report Q3, 2023 Results on Jan 27, 2023

Second quarter 2023 earnings released: EPS: ₹4.19 (vs ₹4.60 in 2Q 2022)

Aarti Drugs Limited to Report Q2, 2023 Results on Oct 20, 2022

Aarti Drugs Limited Appoints Independent Directors

Aarti Drugs Limited to Report Q1, 2023 Results on Jul 27, 2022

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited, Annual General Meeting, Aug 04, 2022

Aarti Drugs' (NSE:AARTIDRUGS) Anemic Earnings Might Be Worse Than You Think

Aarti Drugs Limited Announces Executive Appointments

Aarti Drugs Limited Announces Executive Appointments

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Now 20% undervalued after recent price drop

Price target decreased to ₹678

Less than half of directors are independent

Price target decreased to ₹678

Investor sentiment improved over the past week

Aarti Drugs Limited Announces Board Changes

Insider recently sold ₹79m worth of stock

Now 21% undervalued after recent price drop

Whole-Time Director recently bought ₹761k worth of stock

Chairman recently bought ₹4.3m worth of stock

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Aarti Drugs Limited to Report Q3, 2022 Results on Jan 31, 2022

Now 20% undervalued after recent price drop

Chairman recently bought ₹104k worth of stock

Chairman recently bought ₹15m worth of stock

These 4 Measures Indicate That Aarti Drugs (NSE:AARTIDRUGS) Is Using Debt Reasonably Well

Price target decreased to ₹780

Price target decreased to ₹780